119 related articles for article (PubMed ID: 25000958)
1. Hemostatic and fibrinolytic abnormalities in polycystic ovary syndrome.
Targher G; Zoppini G; Bonora E; Moghetti P
Semin Thromb Hemost; 2014 Jul; 40(5):600-18. PubMed ID: 25000958
[TBL] [Abstract][Full Text] [Related]
2. Increased Coagulation and Decreased Fibrinolysis as Measured with Overall Hemostatic Potential Are Dependent on BMI and Not Associated with PCOS.
Rakusa M; Jensterle M; Božič-Mijovski M; Janez A
Metab Syndr Relat Disord; 2017 May; 15(4):194-198. PubMed ID: 28287900
[TBL] [Abstract][Full Text] [Related]
3. Hemostatic abnormalities and relationships to metabolic and hormonal status in polycystic ovarian syndrome.
Burchall G; Linden MD; Teede H; Piva TJ
Trends Cardiovasc Med; 2011 Jan; 21(1):6-14. PubMed ID: 22498014
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Assessment of the Hemostatic System in Polycystic Ovarian Syndrome.
Burchall GF; Piva TJ; Linden MD; Gibson-Helm ME; Ranasinha S; Teede HJ
Semin Thromb Hemost; 2016 Feb; 42(1):55-62. PubMed ID: 26595150
[TBL] [Abstract][Full Text] [Related]
5. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
Hassa H; Tanir HM; Yildiz Z
Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
[TBL] [Abstract][Full Text] [Related]
6. Coagulation and fibrinolytic indices during the first trimester of pregnancy in women with polycystic ovary syndrome: a preliminary study.
Shan Y; Wang A; Sun Y; Jiang W; Pang B; An Z; Du X; Wang W; Huang Z
Reprod Sci; 2013 Nov; 20(11):1390-7. PubMed ID: 23585337
[TBL] [Abstract][Full Text] [Related]
7. Effects of acupuncture and exercise on insulin sensitivity, adipose tissue characteristics, and markers of coagulation and fibrinolysis in women with polycystic ovary syndrome: secondary analyses of a randomized controlled trial.
Stener-Victorin E; Baghaei F; Holm G; Janson PO; Olivecrona G; Lönn M; Mannerås-Holm L
Fertil Steril; 2012 Feb; 97(2):501-8. PubMed ID: 22154367
[TBL] [Abstract][Full Text] [Related]
8. Polycystic ovary syndrome in men: Stein-Leventhal syndrome revisited.
Kurzrock R; Cohen PR
Med Hypotheses; 2007; 68(3):480-3. PubMed ID: 17134841
[TBL] [Abstract][Full Text] [Related]
9. Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity.
Słopień R; Lewandowski K; Kolacz E; Zawilska K; Warenik-Szymankiewicz A
Gynecol Endocrinol; 2006 Nov; 22(11):651-4. PubMed ID: 17145652
[TBL] [Abstract][Full Text] [Related]
10. Polycystic ovary syndrome in the Indian Subcontinent.
Allahbadia GN; Merchant R
Semin Reprod Med; 2008 Jan; 26(1):22-34. PubMed ID: 18181079
[TBL] [Abstract][Full Text] [Related]
11. Hemostatic and fibrinolytic abnormalities in endocrine diseases: a narrative review.
Targher G; Pichiri I; Zoppini G; Bonora E; Chonchol M
Semin Thromb Hemost; 2009 Oct; 35(7):605-12. PubMed ID: 20013527
[TBL] [Abstract][Full Text] [Related]
12. [Anti-Mullerian hormone in the major phenotypes of polycystic ovary syndrome].
Parahuleva N; Pehlivanov B; Orbecova M; Uchikova E; Ivancheva H
Akush Ginekol (Sofiia); 2014; 53(5):22-7. PubMed ID: 25558667
[TBL] [Abstract][Full Text] [Related]
13. [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].
Parahuleva N; Pehlivanov B; Orbecova M; Deneva T; Uchikova E
Akush Ginekol (Sofiia); 2013; 52 Suppl 1():16-23. PubMed ID: 24294740
[TBL] [Abstract][Full Text] [Related]
14. [Polycystic ovary syndrome: PCOS].
Kitaoka Y
Nihon Rinsho; 1997 Nov; 55(11):3012-9. PubMed ID: 9396305
[TBL] [Abstract][Full Text] [Related]
15. Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome.
Karakurt F; Gumus II; Bavbek N; Kargili A; Koca C; Selcoki Y; Ozbek M; Kosar A; Akcay A
Gynecol Endocrinol; 2008 Sep; 24(9):491-7. PubMed ID: 18958767
[TBL] [Abstract][Full Text] [Related]
16. Polycystic ovary syndrome and its differential diagnosis.
Lane DE
Obstet Gynecol Surv; 2006 Feb; 61(2):125-35. PubMed ID: 16433936
[TBL] [Abstract][Full Text] [Related]
17. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
Oral B; Mermi B; Dilek M; Alanoğlu G; Sütçü R
Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106
[TBL] [Abstract][Full Text] [Related]
18. Exercise decreases anti-müllerian hormone in anovulatory overweight women with polycystic ovary syndrome: a pilot study.
Moran LJ; Harrison CL; Hutchison SK; Stepto NK; Strauss BJ; Teede HJ
Horm Metab Res; 2011 Dec; 43(13):977-9. PubMed ID: 21989557
[TBL] [Abstract][Full Text] [Related]
19. The use of metformin in the management of polycystic ovary syndrome and associated anovulatory infertility: the current evidence.
Leeman L; Acharya U
J Obstet Gynaecol; 2009 Aug; 29(6):467-72. PubMed ID: 19697191
[TBL] [Abstract][Full Text] [Related]
20. Endocrine characteristics of polycystic ovary syndrome (PCOS).
Szilágyi A; Szabó I
Indian J Exp Biol; 2003 Jul; 41(7):694-700. PubMed ID: 15255372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
